RCT: Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder.

Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study – Journal of Affective Disorders

Commentary on Twitter

RCT: In patients with remitted MDD with 10 mg/day of vortioxetine, time to relapse was longer and cumulative relapse rates were lower for vortioxetine 5 mg (19.3%), 10 mg (17.9%), and 20 mg (17.4%) versus placebo (32.5%) over 28 weeks (p<0.05 for all) https://t.co/LzwFaxVt4d pic.twitter.com/Gq3lLTtVcS

— PfOL (@psychopharmacol) March 11, 2022